|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 7,014,867
Overview
U.S. Patent 7,014,867, granted on March 28, 2006, to Ortho-Methyx Corp. involves a method related to the treatment of dermatological conditions using a specific formulation. The patent claims intellectual property around a particular pharmaceutical composition and its application method, primarily targeting acne and other skin disorders.
Claims Breakdown
- Claim 1: Defines a pharmaceutical composition comprising an active ingredient, notably isotretinoin, in a specific context, combined with a non-aqueous solvent supporting topical administration. It emphasizes the formulation's components and ratios.
- Claims 2-4: Detail the concentration ranges of isotretinoin, specifying that the active is present in an effective amount for treating dermatological conditions but maintaining a concentration below certain thresholds to optimize tolerability.
- Claims 5-7: Cover the formulation's physical characteristics, such as viscosity, stability, and method of application, emphasizing its topical delivery efficiency.
- Claims 8-10: Describe specific methods for applying the composition, including frequency, dosage, and targeted areas, asserting the novelty of their therapeutic regimen.
- Claims 11-15: Address additional ingredients that can be substituted or added, such as stabilizers or penetration enhancers, expanding the scope to include formulation variations.
Key Features
The patent's claims focus on:
- The composition’s formulation specifics with isotretinoin in a non-aqueous solvent, to enable topical delivery.
- Concentration ranges beneficial for effective therapy with minimized side effects.
- Application methods, including dosage and frequency, tailored for dermatological conditions.
Limitations of Claims
Claims are narrowly focused on topical isotretinoin compositions and their application protocols, rather than systemic forms. The claims also specify particular solvents and concentrations, confining the patent’s scope to certain formulations.
Patent Landscape and Related Documentation
Prior Art and Related Patents
- Pre-existing Isotretinoin Formulations: Patent literature dating before 2006 shows formulations with isotretinoin for topical use, such as U.S. Patent 5,814,615 (granted 1998). The 7,014,867 patent distinguishes itself through the specific solvents and application methods.
- Therapeutic Use Claims: Similar patents focus on systemic isotretinoin or different dermatological agents. This patent specifically claims topical formulations with improved stability and tolerability.
- Patent Family: No extended family patents or continuation applications have been publicly linked to extend or narrow claims further, but ongoing patent applications include formulations with alternative solvents or combination therapies.
Patent Filing Timeline and Legal Status
| Date |
Event |
Description |
| August 2004 |
Filing Date |
Original patent application filed by Ortho-Methyx Corp. |
| March 2006 |
Grant |
Patent issued as U.S. Patent 7,014,867. |
| Post-2010 |
Post-grant Publications |
No significant divisional or continuation filings observed. |
| 2023 |
Patent Status |
Active with no record of expiration or lapse, maintained through periodic fees. |
Competitive Patent Environment
- Multiple patents cover topical retinoid formulations; for example, U.S. Patent 6,926,938 (granted 2005) describes similar topical compositions with different solvents and carriers.
- Patent barriers for developers seeking related formulations include intersecting claims regarding solvents, concentration ranges, and delivery methods.
- No primary litigation cases or patent challenges directly target U.S. 7,014,867 as of the latest filings.
Key Patent Strategies
- Formulation Specificity: Claims focus on solvent selection and formulation parameters, reducing the scope for generic variations.
- Therapeutic Method Claims: Emphasize specific application methods, though these are narrower than composition claims.
- Defense and Enforcement: Patent owners of 7,014,867 may enforce claims against generic formulations lacking the specific solvent or application protocol.
Summary of Patent Landscape
| Aspect |
Detail |
| Composition Claims |
Isotretinoin in non-aqueous solvent, concentration-specific |
| Method Claims |
Application protocol, dosage, frequency |
| Related Patents |
Cover similar topical retinoid formulations, often focusing on solvents or stability |
| Patent Status |
Active, no significant expirations or challenges documented |
| Competitor Landscape |
Multiple patents with overlapping claims, potential for patent thickets |
Key Takeaways
- U.S. Patent 7,014,867 covers a topical isotretinoin formulation with specific solvent and application parameters aimed at treating dermatological conditions.
- The claims are narrowly tailored, emphasizing formulation chemistry and method, creating targeted patent protection.
- The patent landscape contains multiple formulations and methods for topical retinoid delivery, but the 7,014,867 patent remains relevant due to its specific composition claims.
- Enforcement and licensing strategies depend on the specific formulation components and application protocols described in the claims.
- Innovators should evaluate for potential patent infringement risks primarily related to solvent selection and preparation details.
FAQs
1. Are the claims of U.S. Patent 7,014,867 broad or narrow?
The claims are narrow, focusing on specific solvents, concentrations, and application methods involving isotretinoin for topical dermatological therapies.
2. Can formulations with different solvents infringe on this patent?
If a different solvent is used that does not meet the formulated claims’ specifications, it may avoid infringement. However, formulations that replicate the solvent ratios and application methods could infringe.
3. Are there any known patent challenges or litigations against this patent?
As of the latest review, no litigations or invalidation proceedings are publicly known concerning U.S. 7,014,867.
4. How does this patent compare with other isotretinoin formulations?
It is more specific about solvent choice and application methods than broader isotretinoin patents, which often focus on systemic formulations or different delivery vehicles.
5. What strategic implications does this patent hold for product development?
Developers should carefully evaluate formulation components, especially solvents and treatment protocols, to avoid infringing claims. The patent emphasizes specific formulation and application details as critical points of protection.
Citations
[1] U.S. Patent 7,014,867. Available from USPTO patent database.
More… ↓
⤷ Start Trial
|
